Видео ютуба по тегу Medicines: Ipilimumab

Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
Treatment-free survival results of nivolumab and salvage nivolumab + ipilimumab for accRCC
Dr. Sharpless on Managing Toxicities With Nivolumab/Ipilimumab in Melanoma
Dr. Sharpless on Managing Toxicities With Nivolumab/Ipilimumab in Melanoma
History of Melanoma Immunotherapy - From Freund to Ipilimumab
History of Melanoma Immunotherapy - From Freund to Ipilimumab
New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in Melanoma
New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in Melanoma
Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma
Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma
Ipilimumab Side Effect Management in Melanoma
Ipilimumab Side Effect Management in Melanoma
Success for ipilimumab and nivolumab combo in advanced melanoma
Success for ipilimumab and nivolumab combo in advanced melanoma
Investigating Responses to Nivolumab and Ipilimumab in Advanced RCC
Investigating Responses to Nivolumab and Ipilimumab in Advanced RCC
Cancer Immunotherapy with Nivolumab Plus Ipilimumab Vs. Chemotherapy: Insights from CheckMate 227
Cancer Immunotherapy with Nivolumab Plus Ipilimumab Vs. Chemotherapy: Insights from CheckMate 227
Dr. Shoushtari on the Role of Nivolumab and Ipilimumab in Mucosal Melanoma
Dr. Shoushtari on the Role of Nivolumab and Ipilimumab in Mucosal Melanoma
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma
Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma
Debate: Targeting the immune system with checkpoint inhibitors - Single drug therapy
Debate: Targeting the immune system with checkpoint inhibitors - Single drug therapy
Dr. Sosman on the Mechanism of Action of Ipilimumab in Melanoma
Dr. Sosman on the Mechanism of Action of Ipilimumab in Melanoma
Benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
Benefits and risks of reinduction ipilimumab/nivolumab in patients with melanoma
Ipilimumab/Nivolumab in First-Line mRCC
Ipilimumab/Nivolumab in First-Line mRCC